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PRECLINICAL RESEARCH
he Tyrosine Phosphatase, SHP-1, Is a
egative Regulator of Endothelial Superoxide Formation
lorian Krötz, MD,*† Barbara Engelbrecht, MS,* Martin A. Buerkle, MD,‡ Florian Bassermann, MD,§
anna Bridell, BS,* Torsten Gloe, PHD,* Justus Duyster, MD,§ Ulrich Pohl, MD,* Hae-Young Sohn, MD†
unich, Germany
OBJECTIVES We investigated the role of SH2-domain containing phosphatase-1 (SHP-1) in endothelial
reduced nicotinamide adenine dinucleotide (phosphate) (NAD[P]H)-oxidase–dependent
oxidant production.
BACKGROUND Superoxide (O2
·) generation by endothelial NAD(P)H-oxidase promotes endothelial
dysfunction and atherosclerosis. Signaling pathways that regulate NAD(P)H-oxidase activity
are, however, poorly understood.
METHODS SH2-domain containing phosphatase-1 was inhibited using site-directed magnetofection of
antisense oligodesoxynucleotides (AS-ODN) or short interfering ribonucleic acid (siRNA) in
vitro in human umbilical vein endothelial cells (HUVEC) and in isolated hamster arteries;
O2
· was measured by cytochrome c reduction in vitro. Activities of NAD(P)H-oxidase
activity, phosphatidyl-inositol-3-kinase (PI3K), and SHP-1 were assessed by specific assays;
Rac1 activation was assessed by a pull-down assay.
RESULTS Basal endothelial O2
· release was enhanced after inhibition of endothelial SHP-1 (p 
0.01), which could be prevented by specific inhibition of NAD(P)H-oxidase (p  0.01);
SHP-1 activity was high under basal conditions, further increased by vascular endothelial
growth factor (10 ng/ml, p 0.05), and abolished by SHP-1 AS-ODN treatment (p 0.01),
which also increased NAD(P)H-oxidase activity 3.3-fold (p  0.01). Vascular endothelial
growth factor also induced O2
· release (p  0.01), which was even more enhanced when
SHP-1 was knocked down (p  0.05). The effect of SHP-1 was mediated by inhibition of
PI3K/Rac1-dependent NAD(P)H-oxidase activation (p  0.01); SHP-1 AS-ODN aug-
mented tyrosine phosphorylation of the p85 regulatory subunit of PI3K (p  0.05) and Rac1
activation. The latter was prevented by wortmannin, a blocker of PI3K.
CONCLUSIONS In HUVEC, SHP-1 counteracts basal and stimulated NAD(P)H-oxidase activity by negative
regulation of PI3K-dependent Rac1 activation; SHP-1 thus seems to be an important part of
endothelial antioxidative defense controlling the activity of the O2
·-producing
NAD(P)H-oxidase. (J Am Coll Cardiol 2005;45:1700–6) © 2005 by the American
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.02.039College of Cardiology Foundation
a
a
a
R
o
s
t
t
m
o
t
m
o
i
l
l
l
y
eeduced nicotinamide adenine dinucleotide (phosphate)
NAD[P]H)-oxidase– derived endothelial superoxide
O2
·) production plays a decisive role in the development
f atherosclerosis (1–4). Elevated O2
· levels activate
roatherogenic signalling pathways and stimulate vascular
mooth muscle cell proliferation (4,5), scavenge
ndothelium-derived nitric oxide, and, thus, aggravate en-
othelial dysfunction (2,4).
Activation of vascular NAD(P)H-oxidase contributes
o atherosclerosis development (1,3,6), and expression of
ts subunits is increased in atherosclerotic plaques (7).
he oxidase is constitutively active, but increases its
ctivity upon stimulation more than 2-fold (8). The
nzymatic complex consists of at least five subunits,
From the *Institute of Physiology, †Cardiology, Medical Policlinic, ‡Clinic of
nesthesiology, Ludwig-Maximilians University, Munich, Germany; and §Depart-
ent of Internal Medicine III, TU Munich, Germany. This paper contains part of the
octoral thesis of Barbara Engelbrecht. This study was supported by grants from the
riedrich-Baur-Stiftung and the “Stiftung Münchner Medizinische Wochenschrift”
f the Ludwig-Maximilians University and by a grant from the German Ministry of
cience (BMBF).i
Manuscript received August 21, 2004; revised manuscript received January 4, 2005,
ccepted February 1, 2005.mong them the two membrane-spanning proteins Nox
nd p22phox and the cytosolic subunits p40phox, p47phox,
nd p67phox, which, together with the small GTPase
ac1, associate with the membrane-bound subunits in
rder to form the active oxidase (8,9). At least two events
eem to be necessary for assembly and full activation of
he enzyme complex in endothelial cells. One is the
ranslocation of the small GTPase Rac1 to the plasma
embrane, an event that we have previously described to
ccur in endothelial cells (10). The second is a serine/
hreonin phosphorylation of p47phox, which induces its
embrane translocation (11).
Although signalling events downstream of NAD(P)H-
xidase–dependent O2
· production have been profoundly
nvestigated, there is little evidence for regulating pathways
eading to the enzyme’s activation, particularly in endothe-
ial cells. In addition to the serine/threonin phosphorylation
eading to the activation of p47phox (11), tyrosine phosphor-
lation events seem to be needed for activation of the
ndothelial (10,12), smooth muscle cell (13,14), or platelet
soform (15) of the oxidase.
b
t
c
a
t
1
s
(
e
r
l
s
S
o
n
S
o
m
i
a
M
E
e
c
c
b
(
(
M
p
a
w
n
w
o
a
t
t
a
I
u
M
(
N
c
d
r
(
s
I
t
v
p
m
i
b
a
b
p
m
H
w
(
T
p
t
m
a
s
p
I
t
G
S
i
1
w
t
c
g
m
f
e
G
P
c
c
a
i
p
a
i
2
1701JACC Vol. 45, No. 10, 2005 Krötz et al.
May 17, 2005:1700–6 SHP-1 Inhibits Endothelial NAD(P)H-OxidaseIn previous studies, we showed that tyrosine kinase
lockers inhibit NAD(P)H-oxidase activity, whereas pro-
ein tyrosine phosphatase (PTP) inhibitors markedly in-
reased it (16). In this context, we could demonstrate that
ngiotensin II (AT II) activates SH2-domain containing
yrosine phosphatase-1 (SHP-1) (also called PTN6, PTP-
C, SH-PTP-1) in endothelial cells via its AT-2 receptor
ubtype, which went along with decreased O2
· formation
17); SHP-1, which is preferentially studied in hematopo-
tic cells, is known to be a negative regulator of immune
eceptor signalling in lymphocytes, macrophages, and plate-
ets, in which it is typically coactivated upon cellular
timulation to exert an autoinhibitory function (18–20).
In this study, we investigated whether endothelial cell
HP-1 is a negative regulator of endothelial NAD(P)H-
xidase dependent O2
· formation. Using the novel tech-
ique of magnetofection, we posttranscriptionally silenced
HP-1 using antisense oligodesoxynucleotides (AS-ODN)
r short interfering ribonucleic acid (siRNA). We further-
ore investigated which downstream-signalling targets are
nvolved in SHP-1–dependent regulation of basal and
gonist-induced NAD(P)H-oxidase activity.
ETHODS
ndothelial cell culture. Primary human umbilical vein
ndothelial cells (HUVEC) were harvested from umbilical
ords by digestion with dispase (2.4 U/ml) and grown to
onfluence in medium 199 supplemented with 20% new-
orn calf serum and 20% endothelial growth medium
Promocell, Heidelberg, Germany) as previously described
HUVEC medium) (21).
agnetofection of oligonucleotides. Single-stranded
hosphorothioate AS-ODN or short interfering ribonucleic
cids (siRNAs) were transfected using magnetofection,
hich was previously described as an advantageous tech-
ique for endothelial AS-ODN transfer (21,22). Assays
ere performed 24 h afterwards. Sequences of oligonucle-
tides were (5=-3=) cccttatttactactttcgc for random ODN
nd (5=-3=) ccttgagcagggtctctgcatcc for SHP-1 AS-ODN;
he sequence of the double-stranded siRNA used was (only
Abbreviations and Acronyms
AS-ODN  antisense oligodesoxynucleotide
HUVEC  human umbilical vein endothelial cells
NAD(P)H  reduced nicotinamide adenine dinucleotide
(phosphate)
O2
·  superoxide radical
PI3K  phosphatidyl-inositol-3-kinase
PTP  protein tyrosine phosphatase
AT  angiotensin
RIPA  radioimmunoprecipitation (buffer)
SHP-1  SH2-domain containing tyrosine
phosphatase-1
siRNA  short interfering ribonucleic acid
SS  sodium stibogluconatehe sense strand is given in 5=-3=) guccguguugguugcagcutt, Ns control siRNA (5=-3=) uucuucgaacgugucacgutt was used.
n some assays Cy3-fluorescence-labelled AS-ODN were
sed.
easurement of superoxide radicals (O2
·) and NAD-
P)H-oxidase activity. For superoxide measurements and
ADH-dependent O2
· formation in cell lysates, the
ytochrome c reduction method was used as previously
escribed (22). The O2
·-dependent part of cytochrome c
eduction was calculated from the difference in absorbance
550 nm) between samples incubated with or without
uperoxide dismutase (550nm  21.1/mol/cm).
mmunoprecipitation of SHP-1 and coimmunoprecipi-
ation of p85 and phosphotyrosine. Human umbilical
ein endothelial cells were washed, lysed in radioimmuno-
recipitation (RIPA) buffer, and protein content deter-
ined (22). Aliquots containing 300 g protein were
ncubated with 30 l of protein A-containing Pansorbin
eads (Calbiochem, Schwalbach, Germany) or protein G
garose for 1 h (4°C, gently shaking) to exclude nonspecific
inding. Then samples were incubated with polyclonal
rimary anti-SHP-1 rabbit antibody (C-19) or monoclonal
ouse p85 antibody (B-9, Santa Cruz Biotechnology,
eidelberg, Germany) overnight, followed by incubation
ith either Pansorbin beads for 2 h or protein G agarose
4°C, gentle shaking). After four washing steps using
ris-buffered saline and denaturation at 100°C (5 min),
roteins were separated by SDS-PAGE using standard
echniques (15). For coimmunoprecipitation experiments,
embranes were first blotted using antiphosphotyrosine
ntibody (4G10, Upstate, Hamburg, Germany) followed by
tripping (glycine 200 mmol/l, sodium chloride 500 mmol/l,
H 2.8) and counterstaining for confirming equal loading.
ntensity of bands was quantified using a digital visualiza-
ion system (Gel-Doc 1000, Bio-Rad, München,
ermany).
HP-1 activity assay. Equal amounts of SHP-1 were
mmunoprecipitated, collected on columns equipped with
0 m filters (mobicols, MoBiTec, Göttingen, Germany),
ashed thoroughly using RIPA buffer, and equilibrated in
he phosphatase assay buffer (Hepes 20 mmol/l, sodium
hloride 100 mmol/l, magnesium chloride 5 mmol/l, man-
anese chloride 5 mmol/l, pH 6.5). After addition of 100
mol/l p-nitrophenylphosphate, columns were incubated
or 1 h (37°C), solutions transferred to multiwell plates, and
xtinction measured at 405 nm (SpectraFluor, Tecan,
ermany).
rotein expression and Rac pull-down assay. BCL21-
ompetent cells were transformed with plasmids (pGEX)
ontaining cDNA coding for either GST-PAK or GST
lone (control), grown on LB-ampicillin agarose dishes, and
n LB-ampicillin medium using standard procedures. For
rotein induction, bacteria were grown to an optical density
t 600 nm of 0.7 and induced at 37°C with 0.1 mmol/l
sopropyl-1-thio-D-galactopyranoside and cultivated for
h. They were then lysed using NETN buffer (100 mmol/l
aCl, 1 mmol/l EDTA, 50 mmol/l Tris-HCl [pH 7.4],
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SHP-1 Inhibits Endothelial NAD(P)H-Oxidase May 17, 2005:1700–6.5% Nonidet P-40, 1 mmol/l phenylmethylsulfonylfluo-
ide, 5 mmol/l benzamidine), by addition of lysozyme (100
g/ml), and by sonication, followed by centrifugation and
elleting. Fusion proteins contained in the supernatants
ere collected using glutathione-agarose beads (Amersham
iosciences, Braunschweig, Germany), washed, and the
rocedure controlled by SDS-PAGE. Pull-down assays
ere performed as previously described in detail (23).
aterials. Superoxide dismutase and dispase were from
oche (Penzberg, Germany). Antisense-ODN were from
WG Biotech, Ebersberg, Germany. CombiMAG parti-
les were a kind gift of Dr. C. Bergemann (Chemicell,
erlin, Germany). Sodium stibogluconate (SS) was a kind
ift of Dr. T. Yi (Cleveland, Ohio) (24). The peptides
p91ds-tat and scrambled-tat were kindly provided by Dr.
. Pagano (Detroit, Michigan). Effectene was from Qiagen,
ilden, Germany, and BCL21-competent cells were pur-
hased from Invitrogen, Karlsruhe, Germany. All other
ubstances were obtained from Sigma, Deisenhofen,
ermany.
tatistical analysis. For descriptive purposes, all data are
xpressed as means  SEM. Data were analyzed using
ne-way analysis of variance or Student t test. For paired
xperiments, the respective paired t tests were performed.
ifferences were considered significant when the error
robability level was p  0.05.
ESULTS
HP-1 is constitutively active in endothelial cells and
nocked out by antisense-magnetofection. Short-term
agnetofection of SHP-1 AS-ODN (15 min) resulted in
fficient deprivation of the SHP-1 protein after 24 h (n 4)
Fig 1., inlet). This was associated with a loss of enzymatic
ctivity of SHP-1 (n 3, p 0.01) (Fig. 1). Notably, there
igure 1. SH2-domain containing tyrosine phosphatase-1 (SHP-1) is
onstitutively active in endothelial cells and degraded by antisense-
agnetofection. Magnetofection of antisense oligodesoxynucleotide (AS-
DN) against SHP-1 into human umbilical vein endothelial cells
HUVEC) resulted in deprivation of its protein associated with a loss of
HP-1 activity. Note that there is remarkable activity of SHP-1 in
UVEC grown under control conditions (random ODN, similar activitybserved in untransfected cells, see Fig. 4). **Significantly different vs.
ontrol at p  0.01.
N
fas relevant SHP-1 activity in cells grown under our
xperimental conditions.
nhibition of SHP-1 increases endothelial superoxide
roduction. All means used to block SHP-1 in endothelial
ells significantly increased basal O2
· release. Sodium
tibogluconate, which specifically inhibits SHP-1 at con-
entrations of 10 g/ml (24), increased O2
· release by 81.4
1.5% (n  32, p  0.01) (Figs. 2 and 3). Increasing
ndothelial O2
· release by inhibiting SHP-1 activity ap-
eared to be a nontranscriptional, rapidly occurring event, as
0 min of preincubation with SS (10 g/ml) were sufficient
o achieve the effect (Fig. 2, n  12 for all time points).
igure 2. Pharmacological inhibition of SH2-domain containing tyrosine
hosphatase-1 by sodium stibogluconate (SS) increases basal endothelial
uperoxide (O2
·) production. Pretreatment with SS (10 g/ml) signifi-
antly enhanced O2
· release from human umbilical vein endothelial cells
onolayers. The effect of SS reached significant levels after 30 min of
reincubation, indicating a nontranscriptional mechanism. **Significantly
ifferent vs. control at p  0.01.
igure 3. Degradation of SH2-domain containing tyrosine phosphatase-1
SHP-1) protein increases endothelial O2
· production. Human umbilical
ein endothelial cells O2
· release was enhanced, when SHP-1 was
nhibited by a pharmacological agent (sodium stibogluconate [SS] 10
g/ml) and when its protein was degraded by antisense oligodesoxynucle-
tide (AS-ODN) or short interfering ribonucleic acid (siRNA).
·-Acetylcysteine (NAC) reduced O2 production. *, **Significantly dif-
erent vs. control at p  0.05 and p  0.01, respectively.
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May 17, 2005:1700–6 SHP-1 Inhibits Endothelial NAD(P)H-Oxidaseosttranscriptional deprivation of SHP-1 by AS-ODN
reatment resulted in an even higher O2
· formation (by
70.4  25%, n  34, p  0.01) (Fig. 3), while random
DN had no effect. Using RNA interference to knock out
HP-1 showed similar effects: magnetofection of 200
mol/l of siRNA against SHP-1 increased endothelial O2
·
elease by 165.7  45.5% (n  8, p  0.01) (Fig. 3). The
ntioxidant N-acetylcysteine (1 mmol/l, 30 min) completely
locked endothelial O2
· release (n  3, p  0.05) (Fig. 3).
To test, whether agonist-induced O2
· production was
lso influenced by inhibition of SHP-1, we applied VEGF
10 ng/ml, 30 min) to HUVEC, which not only increased
nzymatic SHP-1 activity significantly (n  5, p  0.05)
Fig. 4A), but also O2
· release by 130.4  19.2% (n  9,
 0.01) (Fig. 4B). When SHP-1 was knocked down using
S-ODN, this increase was further enhanced by another
8%, which was not the case when random ODN were used
igure 4. Influence of vascular endothelial growth factor (VEGF) on
H2-domain containing tyrosine phosphatase-1 (SHP-1) activity and
uperoxide production. (A) Stimulation with VEGF (10 ng/ml) enhanced
asal phosphatase activity of SHP-1 in human umbilical vein endothelial
ells (HUVEC). (B) VEGF (10 ng/ml) also increased HUVEC O2
·
elease, which was further enhanced when SHP-1 was knocked down using
ntisense oligodesoxynucleotide (AS-ODN). *, **Significantly different vs.
ontrol at p  0.05 and p  0.01, respectively; #significantly different vs.
EGF at p  0.05.n  9 each, p  0.05 vs. VEGF) (Fig. 4B).
d
dHP-1 down-regulates NAD(P)H-oxidase–dependent
uperoxide production. To identify the enzyme involved
n O2
· production controlled by SHP-1, we pretreated
UVEC with various inhibitors of potential enzymatic
ources for O2
·. While inhibition of xanthine oxidase
oxypurinol, 300 mol/l, n  4), cyclooxygenase (indo-
ethacin, 20 mol/l, n  3), or cytochrome P450 2C9
sulfaphenazole, 50 mol/l, n  3) had no effect on
S-induced O2
· release (data not shown), specific inhibi-
ion of NAD(P)H-oxidase by the peptide gp91ds-tat abol-
shed the effect of SHP-1 blockade (n  9, p  0.01) (Fig.
A). Direct assessment of the NAD(P)H-oxidase activity
y measuring NADH-dependent O2
· production in ly-
ates of HUVEC confirmed the involvement of NAD(P)H-
xidase: the NAD(P)H-oxidase activity was unaffected in
igure 5. SH2-domain containing tyrosine phosphatase-1 (SHP-1) down-
egulates reduced nicotinamide adenine dinucleotide (phosphate)
NAD[P]H)-oxidase activity. (A) Specific inhibitory peptides against
AD(P)H-oxidase (gp91ds-tat, 100 mol/l) abrogated the increase in
2
· release in human umbilical vein endothelial cell (HUVEC) mono-
ayers that was caused by sodium stibogluconate (SS). (B) NADH-
ependent O2
· production in HUVEC protein lysates was increased
.3-fold after treatment of cells with antisense oligodesoxynucleotide
AS-ODN) against SHP-1 but not with random ODN. *, **Significantly
ifferent vs. control at p  0.05 and p  0.01, respectively; ##significantly
ifferent vs. SS at p  0.01.
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SHP-1 Inhibits Endothelial NAD(P)H-Oxidase May 17, 2005:1700–6andom ODN-treated cells, whereas it was 3.3-fold higher
n cells pretreated with SHP-1 AS-ODN (n 36, p 0.01
s. control and random) (Fig. 5B).
hosphatidyl-inositol-3-kinase (PI3K) is a downstream
arget of endothelial SHP-1. Next, we studied whether
I3K is a target of SHP-1 in HUVEC. We treated
UVEC with an inhibitor of PI3K (wortmannin, 10
mol/l, 30 min) in the presence or absence SHP-1 AS-
DN. Whereas the AS-ODN against SHP-1 induced the
xpected O2
· production, this was prevented when
UVEC were preincubated with wortmannin (n  4, p 
.05) (Fig. 6A), suggesting that SHP-1 under basal condi-
ions down-regulates PI3K with subsequent attenuation in
igure 6. Phosphatidyl-inositol-3-kinase (PI3K) is a downstream target of
ndothelial SH2-domain containing tyrosine phosphatase-1 (SHP-1). (A)
nhibition of PI3K activity by wortmannin (10 nmol/l) abolished the
ncreased O2
· production after treatment with SHP-1 antisense oligodes-
xynucleotide (AS-ODN) or sodium stibogluconate (SS). (B) Co-staining
f immunoprecipitates of the p85 regulatory subunit of PI3K showed
ncreased tyrosine phosphorylation of p85 after knock out of SHP-1.
eans of three independent experiments are shown. *, **Significantly
ifferent vs. random ODN at p  0.05 or p  0.01, respectively; #,
#significantly different vs. SHP-1 AS/SS at p  0.05 or p  0.01,
espectively.AD(P)H-oxidase–dependent O2
· production. Similar
i
ebservations were obtained in experiments using SS and
ortmannin (n  9, p  0.01) (Fig. 6A). To confirm this
ypothesis, we examined whether SHP-1 alters tyrosine
hosphorylation of the p85 regulatory subunit of PI3-
inase. This subunit has previously been shown to inhibit
I3K activity when dephosphorylated (25,26). In fact,
HP-1 AS-ODN treatment increased tyrosine phosphory-
ation of p85 subunit by 88% compared to random ODN
n  6, p  0.05) (Fig. 6B).
HP-1 down-regulates the NAD(P)H-oxidase compo-
ent Rac1. Because Rac1 represents an essential compo-
ent of NAD(P)H-oxidase, we studied whether SHP-1-
ependent inhibition of NAD(P)H-oxidase was due to
ltered Rac1 activation. After SHP-1 AS-ODN treatment
r SHP-1 inhibition by SS, there was a significant increase
n Rac1 activation (pull-down assays, Fig. 7A), as evaluated
y density measurements of GTP-bound Rac1 in compar-
son to total Rac1 (n  3, Fig. 7B). Random ODN had no
uch effect. In accordance with O2
· measurements, Rac1
ctivation was prevented when AS-ODN-treated cells were
ncubated with wortmannin (n  3, not shown), indicating
hat Rac1 is a downstream target of PI3K.
ISCUSSION
n this study, we report that SHP-1 is an important
egulator of NAD(P)H-oxidase– dependent endothelial
2
· production. Our data suggest that SHP-1 is constitu-
ively active in human endothelial cells and, thereby, con-
rols basal NAD(P)H-oxidase activity and O2
· production.
igure 7. Inhibition of SH2-domain containing tyrosine phosphatase-1
SHP-1) enhances Rac1 activation mediated by phosphatidyl-inositol-3-
inase (PI3K). (Top) Pull-down assays of Rac1 human umbilical vein
ndothelial cell revealed increased amounts of active Rac1 (bound to
ST-PAK) after sodium stibogluconate (SS) or antisense oligodes-
xynucleotide (AS-ODN) against SHP-1; SS-induced Rac1-activation
as inhibited by wortmannin (not shown). (Bottom) The ratio between
lot densities of GTP-bound Rac1 to total Rac1 revealed significant
nduction of Rac1 activity by SHP-1 AS-ODN and by SS (means of three
xperiments).
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May 17, 2005:1700–6 SHP-1 Inhibits Endothelial NAD(P)H-Oxidasepon endothelial cell stimulation, its activity can be further
ugmented. It then may serve as an autoinhibitory feedback
echanism to prevent excess O2
· release, as observed after
timulation with VEGF. We further show that SHP-1
nhibits NAD(P)H-oxidase by inhibition of PI3K activity
nd subsequent inactivation of the small GTPase Rac1.
Signalling events leading to endothelial NAD(P)H-
xidase activation are only partly characterized. In most
ases, evidence is from studies in phagocytes. The latter
xpress an NADPH-oxidase that is similar in structure, but
iffers in some features from endothelial NAD(P)H-oxidase
4,7,27,28). In comparison to the endothelial one, which
ses Rac1, the phagocyte oxidase uses Rac2 (9). Another
ajor difference is the isoform of the major large electron-
ransferring subunit, gp91phox (Nox2), which seems to be
ot expressed in all vascular cells. Endothelial cells, how-
ver, express it (28), but also the related isoforms Nox1,
ox3, and Nox4 (1). Data for signalling pathways involved
n the activation of the vascular-type oxidase are rarer and
ften derived from studies in vascular smooth muscle cells
14,27), so the actual situation in endothelial cells remains
ncertain. Nevertheless, it seems that protein kinase C
ctivity leading to serine/threonin phosphorylation and
ubsequent translocation of p47phox (11) as well as translo-
ation oft Rac1 (10) also take place during NAD(P)H-
xidase activation in endothelial cells.
Tyrosine phosphorylation events leading to vascular
AD(P)H-oxidase activation have been described by sev-
ral groups including ours (10,12,14,16,29). In addition, we
ave observed that nonspecific PTP inhibitors dramatically
ncrease O2
· release from endothelial cells (16). This
uggested that PTP exerts inhibitory function when they are
ctive; SHP-1 is a PTP expressed in endothelial cells (17),
hich is well-known to exert autoinhibitory action in
- and T-lymphocytes (18,19,30,31). Interestingly, neutro-
hils from SHP-1–deficient mice have inappropriate acti-
ation patterns associated with an increased oxidant pro-
uction (30). In our study, endothelial SHP-1 controls
hosphorylation of p85, the regulatory subunit of PI3K. It
s known that tyrosine phosphorylation of p85 activates
I3K (26). In our experiments, inhibition of PI3K pre-
ented the enhanced O2
· release caused by SHP-1 AS-
DN. Conversely, SHP-1 AS-ODN enhanced tyrosine
hosphorylation of p85. Both inhibition of SHP-1 by SS
nd by AS-ODN furthermore increased Rac1 activity,
hich was not observed when PI3K was inhibited. This
uggests that Rac1 is downstream of PI3K, which itself is
egulated by SHP-1. Thus, inhibition of PI3K by dephos-
horylation of p85 is the mechanism by which SHP-1
nhibits endothelial NAD(P)H-oxidase. Involvement of
I3K in NAD(P)H-oxidase activation has been suggested
fter observations in smooth muscle cells, where O2
·
elease was inhibited by wortmannin, but the underlying
echanisms remained unclear (14,32). We now observe
hat during SHP-1–dependent NAD(P)H-oxidase activa-
ion, Rac1 is activated in a PI3K-dependent manner, which
1nveils the mechanism by which SHP-1 regulates
AD(P)H-oxidase activity. Recently, Li and Shah (33)
uggested that the active enzymatic complex of NAD(P)H-
xidase is preassembled in endothelial cells, where the
nzyme exhibits constitutive activity. In view of these data,
ur findings suggest that a high turnover of Rac1, which is
egulated by PI3K, could represent a rapid molecular switch
o further regulate the activity of endothelial NAD(P)H-
xidase. In accordance with this hypothesis, enhanced
AD(P)H-oxidase activity after blockade of SHP-1 was
uickly reversed by treatment of cells with a PI3K inhibitor
n our study.
We conclude that SHP-1 is an important regulator of
2
· generation by endothelial NAD(P)H-oxidase under
asal conditions or after stimulation with VEGF. It remains
o be shown whether other stimuli that increase endothelial
2
· release, such as AT II or shear stress, also do so or even
ct by down-regulating the activity of SHP-1. According to
ur findings, any signalling that impairs endothelial SHP-1
ctivity could promote the development of endothelial
ysfunction by enhanced O2
· formation. Thus, decreased
ctivity of SHP-1 may be an important contributor to
therosclerotic disease. On the other hand, because direct
ntervention studies using nonspecific antioxidants failed to
how beneficial effects (34), enhancing or preserving SHP-1
unction in endothelial cells might represent an interesting
ool to counteract increased oxidative stress within the
ascular wall in cardiovascular disease.
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